Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 563 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing MOST POPULAR On legacy giving: “It allows me to give something more meaningful... October 13, 2021 FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung... July 25, 2025 5 Tips for Managing Financial Stress During Cancer April 19, 2022 Happy Holidays from the OncoLink Team December 7, 2023 Load more HOT NEWS New Research in Treating Non-Hodgkin Lymphoma and Predicting the Risk of... Por qué no voy a “superar” los efectos a largo plazo... European Lung Cancer Congress 2024 EMA Recommends Granting a Conditional Marketing Authorisation for Autologous Anti-CD19-Transduced CD3+...
